BYGGMA ASA(OSL:BMA) stock Fundamental Analysis

Fundamental Rating

Overall BMA gets a fundamental rating of 1 out of 10. We evaluated BMA against 19 industry peers in the Building Products industry. Both the profitability and financial health of BMA have multiple concerns. BMA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

BMA had negative earnings in the past year.

BMA had positive earnings in 4 of the past 5 years.

BMA had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

BMA's Return On Assets of -11.46% is on the low side compared to the rest of the industry. BMA is outperformed by 84.21% of its industry peers.

Looking at the Return On Equity, with a value of -36.58%, BMA is doing worse than 78.95% of the companies in the same industry.

BMA has a Return On Invested Capital of 2.42%. This is in the lower half of the industry: BMA underperforms 73.68% of its industry peers.

BMA had an Average Return On Invested Capital over the past 3 years of 6.04%. This is in line with the industry average of 6.14%.

		Industry Rank	Sector Rank
ROA	-11.46%
ROE	-36.58%
ROIC	2.42%

ROA(3y)2.06%

ROA(5y)4.25%

ROE(3y)5.65%

ROE(5y)11.19%

ROIC(3y)6.04%

ROIC(5y)8.48%

1.3 Margins

Looking at the Operating Margin, with a value of 1.57%, BMA is doing worse than 78.95% of the companies in the same industry.

In the last couple of years the Operating Margin of BMA has declined.

BMA's Gross Margin of 49.47% is amongst the best of the industry. BMA outperforms 84.21% of its industry peers.

BMA's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	1.57%
PM (TTM)	N/A
GM	49.47%

OM growth 3Y-53.57%

OM growth 5Y-24.03%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.39%

GM growth 5Y-0.63%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BMA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

Compared to 1 year ago, BMA has about the same amount of shares outstanding.

The number of shares outstanding for BMA has been increased compared to 5 years ago.

BMA has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.00 indicates that BMA is not a great score, but indicates only limited risk for bankruptcy at the moment.

BMA has a Altman-Z score (2.00) which is in line with its industry peers.

A Debt/Equity ratio of 0.94 indicates that BMA is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.94, BMA is not doing good in the industry: 63.16% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.94
Debt/FCF	N/A
Altman-Z	2

ROIC/WACC0.28

WACC8.62%

2.3 Liquidity

A Current Ratio of 0.75 indicates that BMA may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.75, BMA is doing worse than 84.21% of the companies in the same industry.

BMA has a Quick Ratio of 0.75. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of BMA (0.40) is worse than 84.21% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.75
Quick Ratio	0.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -647.91%.

The Revenue has grown by 69.16% in the past year. This is a very strong growth!

BMA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.98% yearly.

EPS 1Y (TTM)-647.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-249.65%

Revenue 1Y (TTM)69.16%

Revenue growth 3Y-2.58%

Revenue growth 5Y3.98%

Sales Q2Q%279.35%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BMA. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BMA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BYGGMA ASA

OSL:BMA (4/25/2025, 7:00:00 PM)

16.5

-0.3 (-1.79%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryBuilding Products

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners3.19%

Ins Owner ChangeN/A

Market Cap1.15B

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.31
P/FCF	N/A
P/OCF	N/A
P/B	1.26
P/tB	1.29
EV/EBITDA	N/A

EPS(TTM)-4.78

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS53.85

BVpS13.07

TBVpS12.81

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-11.46%
ROE	-36.58%
ROCE	3.15%
ROIC	2.42%
ROICexc	2.49%
ROICexgc	2.52%
OM	1.57%
PM (TTM)	N/A
GM	49.47%
FCFM	N/A

ROA(3y)2.06%

ROA(5y)4.25%

ROE(3y)5.65%

ROE(5y)11.19%

ROIC(3y)6.04%

ROIC(5y)8.48%

ROICexc(3y)6.14%

ROICexc(5y)9.7%

ROICexgc(3y)6.2%

ROICexgc(5y)9.87%

ROCE(3y)8.16%

ROCE(5y)11.25%

ROICexcg growth 3Y-60.86%

ROICexcg growth 5Y-30.2%

ROICexc growth 3Y-60.74%

ROICexc growth 5Y-29.96%

OM growth 3Y-53.57%

OM growth 5Y-24.03%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.39%

GM growth 5Y-0.63%

F-ScoreN/A

Asset Turnover1.29

Health

		Industry Rank	Sector Rank
Debt/Equity	0.94
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.75
Quick Ratio	0.4
Altman-Z	2

F-ScoreN/A

WACC8.62%

ROIC/WACC0.28

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-647.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-249.65%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)69.16%

Revenue growth 3Y-2.58%

Revenue growth 5Y3.98%

Sales Q2Q%279.35%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y264.55%

EBIT growth 3Y-54.77%

EBIT growth 5Y-21.01%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens